MX2023002350A - Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. - Google Patents

Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.

Info

Publication number
MX2023002350A
MX2023002350A MX2023002350A MX2023002350A MX2023002350A MX 2023002350 A MX2023002350 A MX 2023002350A MX 2023002350 A MX2023002350 A MX 2023002350A MX 2023002350 A MX2023002350 A MX 2023002350A MX 2023002350 A MX2023002350 A MX 2023002350A
Authority
MX
Mexico
Prior art keywords
compositions
methods
disorders
neurological diseases
patient
Prior art date
Application number
MX2023002350A
Other languages
English (en)
Spanish (es)
Inventor
Gabriel Vargas
Wei Chen
Anthony P Ford
Renee S Martin
Original Assignee
Curasen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curasen Therapeutics Inc filed Critical Curasen Therapeutics Inc
Publication of MX2023002350A publication Critical patent/MX2023002350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/501—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the head, e.g. neuroimaging or craniography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023002350A 2020-09-01 2021-08-31 Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. MX2023002350A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073353P 2020-09-01 2020-09-01
US202163212077P 2021-06-17 2021-06-17
PCT/US2021/048540 WO2022051305A1 (en) 2020-09-01 2021-08-31 Compositions and methods for improving neurological diseases and disorders

Publications (1)

Publication Number Publication Date
MX2023002350A true MX2023002350A (es) 2023-04-26

Family

ID=80491939

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002350A MX2023002350A (es) 2020-09-01 2021-08-31 Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.

Country Status (9)

Country Link
US (1) US20230263749A1 (enExample)
EP (1) EP4208159A4 (enExample)
JP (1) JP2023541379A (enExample)
KR (1) KR20230107211A (enExample)
CN (1) CN116801875B (enExample)
AU (1) AU2021337583A1 (enExample)
CA (1) CA3189243A1 (enExample)
MX (1) MX2023002350A (enExample)
WO (1) WO2022051305A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022185255A1 (en) 2021-03-03 2022-09-09 Lenovo (Singapore) Pte. Ltd. Beam failure detection using multiple sets of reference signals
US20260207568A1 (en) * 2022-12-21 2026-07-23 Curasen Therapeutics, Inc. Compositions and methods for improving neurological diseases and disorders
US20250107713A1 (en) * 2023-09-29 2025-04-03 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods for Confirming Iboga Alkaloid Treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952101A (en) * 1975-04-14 1976-04-20 Smithkline Corporation α-Amino methyl-5-hydroxy-2-pyridinemethanols
NZ226991A (en) * 1987-11-27 1992-03-26 Merck & Co Inc Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors
US5264459A (en) * 1992-07-13 1993-11-23 Arch Development Corporation Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
WO2002032897A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US9320724B2 (en) * 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
WO2018195473A1 (en) * 2017-04-20 2018-10-25 The Brigham And Women's Hospital, Inc. Combinations including beta-adrenoreceptor agonists for treatment of parkinson's disease and movement disorders
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
AU2019287771A1 (en) * 2018-06-14 2021-01-28 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
EP3806957A4 (en) * 2018-06-14 2022-03-16 Curasen Therapeutics, Inc. METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS
US10947196B2 (en) * 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
US20220401415A1 (en) * 2019-10-25 2022-12-22 Curasen Therapeutics, Inc. Methods for treating neurological disorders with alpha1a-ar partial agonists
US11607395B2 (en) * 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
JP7734700B2 (ja) * 2020-06-04 2025-09-05 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニストの形態及び組成物

Also Published As

Publication number Publication date
AU2021337583A1 (en) 2023-05-04
KR20230107211A (ko) 2023-07-14
EP4208159A1 (en) 2023-07-12
CA3189243A1 (en) 2022-03-10
CN116801875B (zh) 2026-06-05
AU2021337583A9 (en) 2024-06-27
WO2022051305A1 (en) 2022-03-10
CN116801875A (zh) 2023-09-22
US20230263749A1 (en) 2023-08-24
JP2023541379A (ja) 2023-10-02
EP4208159A4 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
PH12021553232A1 (en) 2h-indazole derivatives and their use in the treatment of disease
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
MA55199B1 (fr) (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques
JOP20220259A1 (ar) تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
MX2023003348A (es) Compuestos y composiciones como moduladores de señalización tlr.
MX2024014117A (es) Sales de ácido piperidinil-metil-purina-amina-d-tartárico, formas cristalinas y su uso en el tratamiento de enfermedades y condiciones médicas
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
PH12022552447A1 (en) Nlrp3 modulators
EP4357334A3 (en) Conjugated oligonucleotide compounds, methods of making and uses thereof
EP4552693A3 (en) Collagen peptide-based medicament compositions and devices and methods of production and use thereof
JOP20240081A1 (ar) مُعدِّلات الجزيئات الصغيرة لنشاط الجلوكوسيريبروسيد واستخداماتها
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
WO2023043870A8 (en) Chewing gum formulation of lsd and methods of use thereof
MX2025000673A (es) Metodos de administracion de nalbufina
MX2026002937A (es) Nuevas fenilalquilaminas y su uso en el tratamiento de trastornos psiquiatricos
MX2023004539A (es) Compuestos y metodos para el tratamiento de trastornos oculares.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases